Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Sponsor
The University of Hong Kong
Study ID
NCT03390738
Phase
PHASE2
Status
Withdrawn

Conditions

  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal

Study Details

A phase II, open label, single arm, single agent study using nivolumab in patients who failed 2 or more lines of previous chemotherapy for recurrent/metastatic NPC (At least 1 line should include platinum based chemotherapy)

Key Dates

First listed
Jan 4, 2018
Start date
Jun 30, 2018
Status verified
Apr 2021
Primary completion
May 31, 2019
Completion
Jun 30, 2019

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intravenous nivolumab 240mg
    Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.

Primary Outcome Measure

Overall response rate of patients. Response will be assessed by RECISTS 1.1 criteria [ Time Frame: 1 year ]

Related Studies